Article

Sirolimus to be tested in DME patients

Union City, CA-MacuSight Inc. is beginning a phase I study of its lead product candidate in patients with diabetic macular edema (DME).

Union City, CA-MacuSight Inc. is beginning a phase I study of its lead product candidate in patients with diabetic macular edema (DME).

The trial, which has enrolled 30 patients, will test the safety and tolerability of MacuSight's proprietary formulation of sirolimus (originally known as rapamycin) when administered in various doses through two types of ocular injections.

The randomized, open-label, dose-escalation study will treat patients with a single subconjunctival or intravitreal injection of the sirolimus formulation.

She said it also will reduce permeability and "down-regulate" the genes involved in the inflammatory processes related to DME.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
© 2025 MJH Life Sciences

All rights reserved.